- Anti-aging biotech NewLimit raises $435M at $3B+ valuationThe Bay Area startup NewLimit has closed one of biotech's largest private financings of 2026 and expects to start human testing next year for its first anti-aging drug candidate. NewLimit said…Endpoints · 1mo ago↗ source
- What’s next for VEGF? #ASCO26 offered clues, but answers will have to waitCHICAGO — Not long ago, there were hopes that a new class of cancer drugs would repeat the success of Keytruda. Instead, it seems more likely they could end up making up for its weaknesses. Many ...Endpoints · 1mo ago↗ source
- Male contraception startup closes $92.5M Series B; Novartis bets on actinium💸 Funding male contraception: Contraline closed a $92.5 million Series B financing to support a Phase 3 study of a male contraceptive dubbed NES/T. The daily treatment is a gel rubbed on the shoul…